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Toshiaki IbaRecombinant thrombomodulin (rTM) is widely used for
septic disseminated intravascular coagulation (DIC) in
Japan. Tagami and colleagues performed an analysis
using a nationwide administrative database in Japan and
reported that rTM did not reduce the mortality in
pneumonia-associated DIC (37.6 % in the rTM group
vs 37.0 % in the control group, odds ratio: 1.01 (95 %
confidence interval: 0.93 to 1.10)) [1]. They also reported
a similar result in patients with bowel perforation-induced
DIC [2]. These reports indicate that rTM will not be
effective in real clinical practice. In contrast, in a recent
issue of Critical Care, Yoshimura and colleagues reported
that administration of rTM was significantly associated
with reduced mortality in high-risk patients [3]. The same
group also reported in their systematic review that the
probability of a beneficial effect with rTM increases with
increasing baseline risk [4].
Based on these findings, I suppose that rTM is not
properly used currently. The decision based on Japanese
Association of Acute Medicine DIC diagnostic criteria
may not be adequate. As a matter of fact, Tagami
and colleagues performed a very similar analysis for
antithrombin concentrate and reported its efficacy
(odds ratio: 0.85 (95 % confidence interval: 0.75 to
0.97)) [5]. We must remember that the Japanese
Association of Acute Medicine criteria were designed
specifically with the purpose of helping physicians
decide on the timing of anticoagulant treatment, and
antithrombin was the primary anticoagulant at that
time. I therefore propose establishing different criteria,
such as ‘fulfill the Japanese Association of Acute Medicine
DIC criteria and Acute Physiology and Chronic Health
Evaluation II score >24’, for the application of rTM.Correspondence: toshiiba@cf6.so-net.ne.jp
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